美國居民不適用 XM 服務。
S
S

Stryker

交易方向

交易者脈動

技術摘要

小時

財經新聞

Zimmer Biomet beats profit estimates on strong demand for medical devices

Zimmer Biomet beats profit estimates on strong demand for medical devices Aug 7 (Reuters) - Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures. Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
S
Z

Baxter raises full-year profit forecast on robust demand for medical devices

Baxter raises full-year profit forecast on robust demand for medical devices Aug 6 (Reuters) - Baxter International BAX.N on Tuesday raised its annual profit expectations and beat Wall Street estimates for second-quarter profit on strong sales of its medical devices, driven by robust demand for medical care among patients. Shares of the company rose 3% to $35.69 in premarket trading.
S

Teleflex raises 2024 profit forecast on medical device demand

Teleflex raises 2024 profit forecast on medical device demand Aug 1 (Reuters) - Surgical equipment maker Teleflex TFX.N raised its annual profit forecast on Thursday, banking on resilient demand for certain surgical procedures at hospitals to drive sales for its medical devices. The company also said its board authorized a share repurchase program for up to $500 million of common stock.
S
T

Stryker beats Q2 profit estimates on robust demand for medical devices, implants

Stryker beats Q2 profit estimates on robust demand for medical devices, implants July 30 (Reuters) - Stryker Corp SYK.N posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries. On an adjusted basis, the company reported a profit of $2.81 per share for the quarter ended June 30, slightly above analysts' estimates of $2.79 per share.
S

Stryker Q2 Adjusted EPS USD 2.81 Vs. IBES Estimate USD 2.79

BRIEF-Stryker Q2 Adjusted EPS USD 2.81 Vs. IBES Estimate USD 2.79 Jul 30 (Reuters) - Stryker Q2 adjusted EBIT margin 24.6%. Q2 EPS USD 2.14 Q2 revenue USD 5,400 million vs. IBES estimate USD 5,406 million Q2 adjusted net income USD 1,085 million vs. IBES estimate USD 1,072 million Q2 adjusted gross margin 64.2% Q2 net income USD 825 million outlook
S

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明